http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GR-1002776-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d05fc8c0bce4642ffb52322119d00128 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86 |
| filingDate | 1996-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb01a15ea101a5f2292c9d8a02a410a6 |
| publicationDate | 1997-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GR-1002776-B |
| titleOfInvention | EVALUATION OF THE OPERATIVE ACTION OF THE CONTRACT OF ANTITROMBINI-III / USIRINI, NEW DECLARATION OF INFRASTRUCTURE CONDITIONS |
| abstract | A novel and useful method for checking the efficacy of the complex ATTIII/heparin is disclosed and claimed herein. It is based on the performance of two APTT clotting times (the one with the addition of a mixture of ATTIII/heparin, and the other with the addition of buffer) and on the calculation of their ratio. 236 subjects (86 healthy controls and 150 thrombophilic patients) have been studied. To all these patients we applied APTT, PT, and a PC-resistance with classic methods, while the mutation Leiden of the factor V was checked with PCR based method. All the clotting, times were calculated with the fibrin-timer of the Behring. We determined the reproducibility (CV=1.9-3.5 %) and the reference limits of the method (2.8 +- 0.70, and values less than 1,45 were arbitrary defined as abnormal, with a possibility of mistake 5%). We found only one healthy control with abnormal ratio, none with abnormal a PC-resistance ratio and none with factor V Leiden mutation, while 16 thrombophiliacs had abnormal ratio. Some of them corrected their ratio after the dilution of their plasma with normal plasma or purified factor IX or Xa. In conclusion, the ATIII/heparin resistance test reveals new causes of thrombophilia. Its correction with the addition of purified factors leads to the search of new mutations to these factors. |
| priorityDate | 1996-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 29.